Optimization of a gene electrotransfer procedure for efficient intradermal immunization with an hTERT-based DNA vaccine in mice

Molecular Therapy Methods and Clinical Development

Volumn 1, Issue , 2014, Pages 14045-

  Calvet, Christophe Y ^a,b,c   Thalmensi, Jessie ^d   Liard, Christelle ^d   Pliquet, Elodie ^d   Bestetti, Thomas ^d   Huet, Thierry ^d   Langlade Demoyen, Pierre ^d   Mir, Lluis M ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b France   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d Invectys   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; LUCIFERASE; PLASMID DNA; TELOMERASE REVERSE TRANSCRIPTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DNA IMMUNIZATION; DRUG CYTOTOXICITY; ELECTROPORATION; FEMALE; GENE EXPRESSION; IN VIVO GENE TRANSFER; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT; REPORTER GENE; SKIN FLAP; TARGET CELL; TRANSGENE; VACCINE IMMUNOGENICITY;

EID: 84955706154     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2014.45     Document Type: Article

References (37)

1. 1 André, FM, Gehl, J, Sersa, G, Préat, V, Hojman, P, Eriksen, J, et al. Efficiency of high- and low-voltage pulse combinations for gene electrotransfer in muscle, liver, tumor, and skin. Hum Gene Ther 19 (2008), 1261–1271.
2. 2 Gothelf, A, Gehl, J, Gene electrotransfer to skin; review of existing literature and clinical perspectives. Curr Gene Ther 10 (2010), 287–299.
3. 3 Rochard, A, Scherman, D, Bigey, P, Genetic immunization with plasmid DNA mediated by electrotransfer. Hum Gene Ther 22 (2011), 789–798.
4. 4 Andre, FM, Mir, LM, Nucleic acids electrotransfer in vivo: mechanisms and practical aspects. Curr Gene Ther 10 (2010), 267–280.
5. 5 Rosazza, C, Buntz, A, Rieß, T, Wöll, D, Zumbusch, A, Rols, MP, Intracellular tracking of single-plasmid DNA particles after delivery by electroporation. Mol Ther 21 (2013), 2217–2226.
6. 6 Combadiere, B, Liard, C, Transcutaneous and intradermal vaccination. Hum Vaccin 7 (2011), 811–827.
7. 7 Eschenburg, G, Stermann, A, Preissner, R, Meyer, HA, Lode, HN, DNA vaccination: using the patient's immune system to overcome cancer. Clin Dev Immunol, 2010, 2010, 169484.
8. 8 Kutzler, MA, Weiner, DB, DNA vaccines: ready for prime time?. Nat Rev Genet 9 (2008), 776–788.
9. 9 Vesely, MD, Kershaw, MH, Schreiber, RD, Smyth, MJ, Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29 (2011), 235–271.
10. 10 Stevenson, FK, Palucka, K, Understanding and activating immunity against human cancer. Curr Opin Immunol 22 (2010), 212–214.
11. 11 Braumüller, H, Wieder, T, Brenner, E, Aßmann, S, Hahn, M, Alkhaled, M, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 494 (2013), 361–365.
12. 12 Disis, ML, Bernhard, H, Jaffee, EM, Use of tumour-responsive T-cells as cancer treatment. Lancet 373 (2009), 673–683.
13. 13 Mir, LM, Moller, PH, André, F, Gehl, J, Electric pulse-mediated gene delivery to various animal tissues. Adv Genet 54 (2005), 83–114.
14. 14 Satkauskas, S, André, F, Bureau, MF, Scherman, D, Miklavcic, D, Mir, LM, Electrophoretic component of electric pulses determines the efficacy of in vivo DNA electrotransfer. Hum Gene Ther 16 (2005), 1194–1201.
15. 15 Favard, C, Dean, DS, Rols, MP, Electrotransfer as a non viral method of gene delivery. Curr Gene Ther 7 (2007), 67–77.
16. 16 Gothelf, A, Mahmood, F, Dagnaes-Hansen, F, Gehl, J, Efficacy of transgene expression in porcine skin as a function of electrode choice. Bioelectrochemistry 82 (2011), 95–102.
17. 17 Daugimont, L, Baron, N, Vandermeulen, G, Pavselj, N, Miklavcic, D, Jullien, MC, et al. Hollow microneedle arrays for intradermal drug delivery and DNA electroporation. J Membr Biol 236 (2010), 117–125.
18. 18 Vandermeulen, G, Staes, E, Vanderhaeghen, ML, Bureau, MF, Scherman, D, Préat, V, Optimisation of intradermal DNA electrotransfer for immunisation. J Control Release 124 (2007), 81–87.
19. 19 Roos, AK, Eriksson, F, Timmons, JA, Gerhardt, J, Nyman, U, Gudmundsdotter, L, et al. Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS ONE, 4, 2009, e7226.
20. 20 Beatty, GL, Vonderheide, RH, Telomerase as a universal tumor antigen for cancer vaccines. Expert Rev Vaccines 7 (2008), 881–887.
21. 21 Buseman, CM, Wright, WE, Shay, JW, Is telomerase a viable target in cancer?. Mutat Res 730 (2012), 90–97.
22. 22 Gothelf, A, Gehl, J, What you always needed to know about electroporation based DNA vaccines. Hum Vaccin Immunother 8 (2012), 1694–1702.
23. 23 Senovilla, L, Vacchelli, E, Garcia, P, Eggermont, A, Fridman, WH, Galon, J, et al. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology, 2, 2013, e23803.
24. 24 Villemejane, J, Mir, LM, Physical methods of nucleic acid transfer: general concepts and applications. Br J Pharmacol 157 (2009), 207–219.
25. 25 Aurisicchio, L, Mancini, R, Ciliberto, G, Cancer vaccination by electro-gene-transfer. Expert Rev Vaccines 12 (2013), 1127–1137.
26. 26 Drabick, JJ, Glasspool-Malone, J, King, A, Malone, RW, Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization. Mol Ther 3 (2001), 249–255.
27. 27 Miklavcic, D, Semrov, D, Mekid, H, Mir, LM, A validated model of in vivo electric field distribution in tissues for electrochemotherapy and for DNA electrotransfer for gene therapy. Biochim Biophys Acta 1523 (2000), 73–83.
28. 28 Gehl, J, Sorensen, TH, Nielsen, K, Raskmark, P, Nielsen, SL, Skovsgaard, T, et al. In vivo electroporation of skeletal muscle: threshold, efficacy and relation to electric field distribution. Biochim Biophys Acta 1428 (1999), 233–240.
29. 29 Ivorra, A, Al-Sakere, B, Rubinsky, B, Mir, LM, Use of conductive gels for electric field homogenization increases the antitumor efficacy of electroporation therapies. Phys Med Biol 53 (2008), 6605–6618.
30. 30 Corovic, S, Al Sakere, B, Haddad, V, Miklavcic, D, Mir, LM, Importance of contact surface between electrodes and treated tissue in electrochemotherapy. Technol Cancer Res Treat 7 (2008), 393–400.
31. 31 Miklavcic, D, Corovic, S, Pucihar, G, Pavselj, N, Importance of tumour coverage by sufficiently high local electric field for effective electrochemotherapy. EJC Suppl 4 (2006), 45–51.
32. 32 Rohrlich, PS, Cardinaud, S, Firat, H, Lamari, M, Briand, P, Escriou, N, et al. HLA-B*0702 transgenic, H-2KbDb double-knockout mice: phenotypical and functional characterization in response to influenza virus. Int Immunol 15 (2003), 765–772.
33. 33 Rodriguez, F, Zhang, J, Whitton, JL, DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol 71 (1997), 8497–8503.
34. 34 Wang, Q, Lei, C, Wan, H, Liu, Q, Improved cellular immune response elicited by a ubiquitin-fused DNA vaccine against Mycobacterium tuberculosis. DNA Cell Biol 31 (2012), 489–495.
35. 35 Adotévi, O, Mollier, K, Neuveut, C, Cardinaud, S, Boulanger, E, Mignen, B, et al. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses. Clin Cancer Res 12 (2006), 3158–3167.
36. 36 Cortez-Gonzalez, X, Sidney, J, Adotevi, O, Sette, A, Millard, F, Lemonnier, F, et al. Immunogenic HLA-B7-restricted peptides of hTRT. Int Immunol 18 (2006), 1707–1718.
37. 37 Durward, M, Harms, J, Splitter, G, Antigen specific killing assay using CFSE labeled target cells. J Vis Exp, 45, 2010 http://www.jove.com.gate1.inist.fr/video/2250/antigen-specific-in-vivo-killing-assay-using-cfse-labeled-target-cells.